P/E ratio for Athersys (ATHX)

P/E ratio history for Athersys from 2007 to 2023

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Amgen AMGN	23.7	-532,977.71%	🇺🇸 USA
Pfizer PFE	15.9	-358,003.24%	🇺🇸 USA
Bristol-Myers Squibb BMY	12.3	-277,234.75%	🇺🇸 USA
Moderna MRNA	-7.44	166,931.61%	🇺🇸 USA
Johnson & Johnson JNJ	11.7	-262,735.65%	🇺🇸 USA
United States Lime & Minerals USLM	6.81	-152,997.69%	🇺🇸 USA
Arena Pharmaceuticals ARNA	N/A	N/A	🇺🇸 USA
Merck MRK	64.4	-1,444,459.16%	🇺🇸 USA
Sanofi SNY	18.3	-411,266.10%	🇫🇷 France

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.